TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Progression of allograft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute cellular rejection (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urine concentrations of canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in score on computer game task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adverse reactions (AR) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: St. George's Respiratory Questionnaire (SGRQ) scoring
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nebulization tolerability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Propofol Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iris Vessel Geometric Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption Rescue Analgesia - i.v. opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Pulmonary function analysis (spirometry): forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in analysis of the heart rate variability to study the responses of the autonomic nervous system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 6-Minute Walk Test (Adapted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression of acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Risk Factors for Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of subjects with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Annual Rate of Sickle Cell-related Pain Crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Investigator's Global Assessment (IGA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of 2-butanol in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of Cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Dynamics of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamics of glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamics of insulin dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in wrist extension force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized confirmed relapse rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first confirmed relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Expanded Disability Status Scale (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Severe Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Diabetic Ketoacidosis (DKA)
Endpoint domain: Adverse events/effects
Primary endpoint: Glycated Hemoglobin (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time in Range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose of aflibercept
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Reduction in Kmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of disease progression in bone metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bilirubin change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in time-on-target score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Decision Self Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heart failure related hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Additional costs/savings resulting from the service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HBsAg decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy of needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rate at day 21 after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate at day 21 after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion factor at day 21 after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functionality of pelvic floor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Local SCORing Atopic Dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: G2+ gastrointestinal and genitourinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Ventricular Remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: embryonic aneuploidy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Patients With Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of specific immune cells in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MEP (Motor Evoked Potential)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TOF (Train of Four)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose response after second meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ECG parameter of QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of M5181
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma concentration (Cmax) of M5181
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of aGVHD of grade II to IV
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary renin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiac chamber volume loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain and function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-Cancer-specific change in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence rate ratio of colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate ratio of gastric cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate ratio of esophageal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change of mRNA cytokine expression in induced sputum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of miRNA and mRNA cytokine expression in nose mucosa samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breathing Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Engage in Mental Health Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Center for Epidemiological Studies Depression Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of smoking relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Retear Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in MADRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bech Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in IDS-CR Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity following PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious and noninfectious complication
Endpoint domain: Adverse events/effects
Primary endpoint: Pulse Pressure Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: the incidence of extracorporeal membrane oxygenation(ECMO) for neonates in group 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the incidence of bronchopulmonary dysplasia(BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain in the neck/shoulder and back
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fitness (VO2-max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral disposition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kinetic of GLP-1 secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total amount of piritramide delivered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Concentration of tumor micrometastasis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clindamycin AUC at steady state and after rifampicin introduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhaler Use Correctness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete closure of the index wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma FVIII activity at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the presence and density of asexual parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in the presence and severity of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the presence of recurrent infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: end stage renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: life-expectancy
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Scored as Responder
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reported condom use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Persistent abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intestinal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abdominal wall sinus or fistula formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-operative incisional pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: DAT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change in the Longest Diameter of the Breast MRI Target Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Days Until Engraftment Criteria Were Met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinically significant abnormalities for laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to end of agitation episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with SLN identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change of QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean Value of Lipoprotein Resistance to LPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Number of Passes to Establish Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum observed drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in urine pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemophilia Joint Health Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional Independence Score in Hemophilia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tampa Kinesiophobia Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Benefit (CR, PR, SD lasting >= 24 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite Cardiovascular Outcome for Thiazolidinedione (TZD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Outcome for Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-300 minutes of intact Proinsulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in Depression severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Anxiety severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative rate of molecular response 4.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: 2 year PSA recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bladder shape after emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relapse or exacerbation of symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of urinary bladder injury
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Non-inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ovarian function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Usability of the robot - Fixation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the robot - Applicability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant feeling of safety/comfort - Robot support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical comorbidities as predictors of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased height and weight as predictors of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking history and alcohol intake as predictors of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiographic variables as predictors of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Holter monitor variables as predictors of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiographic variables as predictors of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attendance and compliance to healthy eating plan
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Attendance and compliance to group exercise class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Smoothie consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC (AUClast, AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive intracranial pressure (ICP) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Second non-invasive intracranial pressure (ICP) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Air hunger measured by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of cannabidiol oral administration
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep factors
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pharmacokinetics of nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metaphase II oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Indication for Permanent Pacemaker Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Kidney Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in Hepatic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in the Monthly Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Mild, Moderate, and Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Terbutaline concentrations in serum and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Re-Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: graft function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular (LV) Volume Index at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Left Ventricular (LV) Mass Index at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor Response Through Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual Analog Scale (VAS) 1 hour post dose at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the VAS-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of MoCA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of MMSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Pneumothorax (Grade 2+)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Self-Compassion at Post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing